Contact this trialFirst, we need to learn more about you.
PCNA inhibitor
ATX-101 for Liposarcoma
Recruiting1 awardPhase 2
New York, New York
This trial is testing a new IV drug called ATX-101 for patients with specific types of cancer (LPS and LMS) who haven't had success with other treatments. ATX-101 blocks a protein interaction that helps cancer cells survive, potentially making it an effective treatment option.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service